Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death.
|Abstract||To examine the relationship between the recently defined Gleason grade groups and prostate cancer-specific mortality.|
Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
|Journal Title||american journal of clinical pathology|
|Publication Year Start||2017-01-01|
PMID- 28395050 OWN - NLM STAT- MEDLINE DA - 20170410 DCOM- 20170414 LR - 20170414 IS - 1943-7722 (Electronic) IS - 0002-9173 (Linking) VI - 147 IP - 3 DP - 2017 Mar 01 TI - Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death. PG - 273-277 LID - 10.1093/ajcp/aqw212 [doi] AB - Objectives: To examine the relationship between the recently defined Gleason grade groups and prostate cancer-specific mortality. Methods: If the probability of prostate cancer-specific death is symbolized as P(PSD), the probability of biochemical failure is symbolized as P(BF), and the probability of prostate cancer-specific death after biochemical failure is symbolized as P(PSD | BF), then the rules of probability provide a way to estimate P(PSD) as P(PSD) = P(PSD | BF) * P(BF) Using this model and data from the literature for P(PSD | BF) and P(BF), I estimate here values of P(PSD) for the five newly described Gleason grade groups. Results: The expected probability of prostate cancer- specific death is closely related to the new Gleason grade groups and ranges from a low of 0.014 for grade group 1 to a high of 0.15 for grade group 5. Conclusions: Although using the original study patient population may require years of additional follow-up to examine prostate cancer-specific mortality, the evidence available now indicates that these new Gleason grade groups relate to prostate cancer-specific mortality. FAU - Vollmer, Robin T AU - Vollmer RT AD - From the VA and Duke University Medical Centers, Durham, NC. LA - eng PT - Journal Article PL - England TA - Am J Clin Pathol JT - American journal of clinical pathology JID - 0370470 RN - EC 184.108.40.206 (Prostate-Specific Antigen) SB - AIM SB - IM MH - Humans MH - Male MH - *Models, Statistical MH - *Neoplasm Grading MH - Prostate-Specific Antigen/blood MH - Prostatic Neoplasms/blood/diagnosis/*mortality/*pathology OTO - NOTNLM OT - Biochemical failure OT - Gleason grading OT - PSA OT - Prostate cancer OT - Prostate cancer-specific mortality EDAT- 2017/04/11 06:00 MHDA- 2017/04/15 06:00 CRDT- 2017/04/11 06:00 AID - 3053465 [pii] AID - 10.1093/ajcp/aqw212 [doi] PST - ppublish SO - Am J Clin Pathol. 2017 Mar 1;147(3):273-277. doi: 10.1093/ajcp/aqw212.
<?xml version="1.0" encoding="UTF-8"?> <b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" > </b:Sources>